Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
July 01, 2021 07:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2021 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
June 04, 2021 03:45 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
May 26, 2021 08:00 ET
|
Pharvaris N.V.
RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceedingHAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in...
Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer
May 12, 2021 07:00 ET
|
Pharvaris N.V.
Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients ZUG, Switzerland, May 12, 2021 ...
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
April 29, 2021 16:15 ET
|
Pharvaris N.V.
RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAEOpen IND for the prophylactic evaluation of PHVS416Strong pre-IPO cash and cash equivalents balance of €98.6...
Pharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
April 21, 2021 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
Pharvaris to Participate in BioCapital Europe
March 04, 2021 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
February 26, 2021 08:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
February 19, 2021 10:00 ET
|
Pharvaris N.V.
ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative...